Main menu

Overcoming cisplatin resistance in TP53-null colon cancer organoids


Cisplatin chemotherapy in colorectal cancer (CRC) often fails due to drug resistance, particularly in TP53-deficient tumours as TP53 mutations impair apoptotic responses. By leveraging Oxford Nanopore sequencing and CRISPR-based functional genomics, Khalili et al. uncovered new therapeutic targets for TP53-null CRC. While still in the early stages, this research has the potential to improve patient outcomes through targeted treatment strategies in the future.

Key points:

  • Tumour cells with TP53 mutations compensate for DNA damage by relying on alternative repair pathways

  • Using a genome-wide CRISPR knockout screen, researchers pinpointed DNA repair pathway genes, including FANCL, ERCC6, and BRIP1, as key mediators of drug resistance

  • Oxford Nanopore sequencing validated CRISPR screening results, providing high-resolution confirmation of guide RNA depletion and structural changes in resistant tumour cells

  • Inhibition of FANCL, ERCC6, and BRIP1 significantly increased cisplatin sensitivity, suggesting that blocking these pathways could potentially enhance chemotherapy effectiveness

  • This research supports precision oncology, demonstrating how genetic profiling could guide personalised therapies in the future

Sample type: colon cancer organoids

Kit: Native Barcoding Kit

Authors: Sana Khalili, Paige Heine, Minou Khazan, Carolyn E. Banister, Sidney E. Morrison, Phillip J. Buckhaults

Getting started

Buy a MinION starter pack Nanopore store Sequencing service providers Channel partners

Nanopore technology

Subscribe to Nanopore updates Resources and publications What is the Nanopore Community

About Oxford Nanopore

News Company timeline Sustainability Leadership team Media resources & contacts For investors For partners Working at Oxford Nanopore Current vacancies Commercial information BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
Spanish flag